Jinhe Accounts Payable vs Non Currrent Assets Other Analysis

002688 Stock   4.38  0.16  3.52%   
Jinhe Biotechnology financial indicator trend analysis is infinitely more than just investigating Jinhe Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jinhe Biotechnology is a good investment. Please check the relationship between Jinhe Biotechnology Accounts Payable and its Non Currrent Assets Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Accounts Payable vs Non Currrent Assets Other

Accounts Payable vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jinhe Biotechnology Accounts Payable account and Non Currrent Assets Other. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Jinhe Biotechnology's Accounts Payable and Non Currrent Assets Other is 0.42. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Jinhe Biotechnology Co, assuming nothing else is changed. The correlation between historical values of Jinhe Biotechnology's Accounts Payable and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Jinhe Biotechnology Co are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Accounts Payable i.e., Jinhe Biotechnology's Accounts Payable and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.42
Relationship DirectionPositive 
Relationship StrengthWeak

Accounts Payable

An accounting item on the balance sheet that represents Jinhe Biotechnology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Jinhe Biotechnology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.
Most indicators from Jinhe Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jinhe Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
The current year's Selling General Administrative is expected to grow to about 167.5 M, whereas Tax Provision is forecasted to decline to about 6.7 M.
 2021 2022 2023 2024 (projected)
Operating Income230.9M172.0M187.7M167.7M
Total Revenue2.1B2.1B2.2B1.5B

Jinhe Biotechnology fundamental ratios Correlations

0.960.480.950.830.970.680.910.820.890.751.00.40.750.990.830.850.90.590.970.860.940.790.970.470.34
0.960.390.990.680.970.750.990.710.870.640.960.310.640.960.810.770.840.380.990.770.990.680.890.320.14
0.480.390.380.560.38-0.180.350.560.50.520.480.30.520.440.420.520.350.380.410.540.380.60.540.430.46
0.950.990.380.680.970.760.980.70.860.630.950.390.630.950.740.780.870.40.980.771.00.660.880.290.19
0.830.680.560.680.720.30.60.950.690.890.820.520.890.80.620.930.740.830.70.960.680.890.860.540.6
0.970.970.380.970.720.780.940.70.890.680.960.310.680.970.780.790.880.50.970.790.960.630.890.30.28
0.680.75-0.180.760.30.780.750.240.570.290.680.090.290.690.560.40.680.180.750.40.740.240.580.090.0
0.910.990.350.980.60.940.750.640.850.520.920.290.520.910.790.730.820.260.980.710.980.650.850.310.08
0.820.710.560.70.950.70.240.640.680.870.810.430.870.790.630.880.740.670.720.930.710.90.850.560.41
0.890.870.50.860.690.890.570.850.680.610.890.420.610.870.810.770.790.510.890.740.830.650.820.380.26
0.750.640.520.630.890.680.290.520.870.610.710.361.00.760.540.80.60.810.640.920.630.70.730.330.42
1.00.960.480.950.820.960.680.920.810.890.710.390.710.980.850.840.910.540.980.850.940.810.980.520.32
0.40.310.30.390.520.310.090.290.430.420.360.390.360.370.020.540.360.580.310.470.390.430.370.080.51
0.750.640.520.630.890.680.290.520.870.611.00.710.360.760.540.80.60.810.640.920.630.70.730.330.42
0.990.960.440.950.80.970.690.910.790.870.760.980.370.760.810.820.840.590.960.850.940.740.940.380.28
0.830.810.420.740.620.780.560.790.630.810.540.850.020.540.810.610.720.330.850.640.710.730.860.680.03
0.850.770.520.780.930.790.40.730.880.770.80.840.540.80.820.610.750.710.770.970.770.840.840.380.56
0.90.840.350.870.740.880.680.820.740.790.60.910.360.60.840.720.750.460.870.740.850.730.90.570.39
0.590.380.380.40.830.50.180.260.670.510.810.540.580.810.590.330.710.460.40.760.380.540.570.240.67
0.970.990.410.980.70.970.750.980.720.890.640.980.310.640.960.850.770.870.40.780.970.710.920.410.16
0.860.770.540.770.960.790.40.710.930.740.920.850.470.920.850.640.970.740.760.780.770.840.850.420.49
0.940.990.381.00.680.960.740.980.710.830.630.940.390.630.940.710.770.850.380.970.770.660.870.280.18
0.790.680.60.660.890.630.240.650.90.650.70.810.430.70.740.730.840.730.540.710.840.660.890.760.38
0.970.890.540.880.860.890.580.850.850.820.730.980.370.730.940.860.840.90.570.920.850.870.890.640.38
0.470.320.430.290.540.30.090.310.560.380.330.520.080.330.380.680.380.570.240.410.420.280.760.640.19
0.340.140.460.190.60.280.00.080.410.260.420.320.510.420.280.030.560.390.670.160.490.180.380.380.19
Click cells to compare fundamentals

Jinhe Biotechnology Account Relationship Matchups

Jinhe Biotechnology fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets3.3B3.4B4.1B4.5B5.5B5.7B
Short Long Term Debt Total1.2B1.3B1.0B1.6B2.3B2.4B
Other Current Liab19.9M1.9M33.1M78.1M14.2M21.0M
Total Current Liabilities1.1B1.4B1.2B1.7B2.3B2.4B
Total Stockholder Equity1.7B1.6B2.4B2.2B2.2B1.3B
Property Plant And Equipment Net973.1M1.0B1.2B1.6B2.1B2.2B
Current Deferred Revenue44.7M75.7M87.4M25.7M212.1M222.7M
Net Debt834.2M1.0B490.4M1.1B1.7B1.8B
Retained Earnings498.9M453.0M481.1M556.3M560.1M344.1M
Accounts Payable152.0M97.0M122.0M263.1M254.9M267.7M
Cash361.9M314.8M517.7M491.4M608.1M328.1M
Non Current Assets Total2.1B2.1B2.4B2.8B3.4B3.6B
Non Currrent Assets Other52.6M69.1M178.6M109.5M58.6M58.5M
Cash And Short Term Investments361.9M314.8M517.7M491.4M608.6M328.1M
Net Receivables436.5M444.7M526.3M534.5M710.8M746.4M
Liabilities And Stockholders Equity3.3B3.4B4.1B4.5B5.5B5.7B
Non Current Liabilities Total392.0M253.9M204.3M415.7M679.8M713.8M
Inventory429.6M447.3M577.2M675.9M670.6M349.6M
Other Current Assets12.7M33.4M28.8M44.7M49.6M52.0M
Other Stockholder Equity401.6M401.2M1.1B736.3M736.3M506.0M
Total Liab1.5B1.6B1.4B2.1B2.9B3.1B
Total Current Assets1.2B1.2B1.6B1.7B2.0B1.0B
Short Term Debt928.7M1.2B921.1M1.3B1.8B1.9B
Intangible Assets735.2M683.4M714.4M710.7M743.7M436.7M
Other Liab124.6M118.9M117.3M111.8M128.6M104.4M
Property Plant Equipment973.1M1.0B1.2B1.6B1.9B2.0B
Long Term Debt267.4M135M87M296.2M497.5M262.5M
Good Will326.7M309.9M296.0M298.9M497.9M314.3M
Net Tangible Assets677.8M679.4M1.5B1.3B1.5B897.7M
Deferred Long Term Liab68.7M69.4M75.4M88.3M101.6M60.6M
Short Long Term Debt881.7M1.1B833.9M1.2B1.7B937.8M
Short Term Investments(10.3M)(14.0M)(6.2M)507.7K456.9K479.7K
Non Current Liabilities Other76.1M26.2M11.9M11.6M10.5M10.0M
Net Invested Capital2.8B2.9B3.4B3.8B4.4B3.5B
Net Working Capital95.4M(132.9M)486.3M81.9M(217.7M)(206.9M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jinhe Stock

Balance Sheet is a snapshot of the financial position of Jinhe Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Jinhe Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jinhe Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jinhe currently owns. An asset can also be divided into two categories, current and non-current.